Stephanie Miller
Physician Assistant · Owensboro, KYNPI 1700287745
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 674 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 20.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,846, 3.7 times the $1,030 reported in 2021. Among physician assistant clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 674 payments — averaging $17.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
- AbbVie$2K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Johnson & Johnson$918
- Regeneron Healthcare Solutions, Inc.$650
- Sanofi$557
- plus $4K from 28 others
What the payments were for
- Food & beverage$11,741100%
- Education$160%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 144 | $2,368 |
| AbbVie | 141 | $2,312 |
| Takeda Pharmaceuticals U.S.A., Inc. | 57 | $1,048 |
| Johnson & Johnson | 53 | $918 |
| Regeneron Healthcare Solutions, Inc. | 33 | $650 |
| Sanofi | 30 | $557 |
| QOL Medical, LLC | 25 | $471 |
| Gilead | 22 | $423 |
| Pfizer | 21 | $363 |
| Ardelyx, Inc. | 17 | $354 |
| Lilly USA, LLC | 17 | $332 |
| Intercept Pharmaceuticals, Inc. | 16 | $281 |
| Phathom Pharmaceuticals, Inc. | 19 | $257 |
| Ironwood Pharmaceuticals, Inc | 14 | $255 |
| Madrigal Pharmaceuticals | 11 | $235 |
| Bristol Myers Squibb | 9 | $159 |
| Merck | 7 | $114 |
| Alnylam Pharmaceuticals Inc. | 4 | $87 |
| Braintree Laboratories, Inc. | 5 | $81 |
| Fresenius Kabi USA, LLC | 5 | $79 |
| Aimmune Therapeutics, Inc. | 3 | $75 |
| Nestle Healthcare Nutrition Inc. | 3 | $55 |
| Boehringer Ingelheim | 3 | $52 |
| Celltrion USA Inc. | 2 | $38 |
| Organon | 2 | $33 |
| Ipsen Biopharmaceuticals, Inc | 2 | $31 |
| Medtronic | 2 | $26 |
| Supernus Pharmaceuticals, Inc. | 1 | $17 |
| Amgen | 1 | $16 |
| Ferring Pharmaceuticals Inc. | 1 | $16 |
| Daiichi Sankyo Inc. | 1 | $15 |
| Novo Nordisk | 1 | $14 |
| Azurity Pharmaceuticals, Inc. | 1 | $14 |
| Dynavax Technologies Corporation | 1 | $12 |
How this compares
$11,757 in reported general payments places this provider in the 95th percentile of 1,448 physician assistant providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 15 | $390,498 |
| XifaxanRifaximin | 18 | $51,995 |
| CreonLipase/Protease/Amylase | 12 | $36,485 |
| LinzessLinaclotide | 20 | $23,078 |
| Dexlansoprazole DrDexlansoprazole | 49 | $9,389 |
| Colestipol Hcl | 75 | $4,804 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 27 | $4,589 |
| DexilantDexlansoprazole | 11 | $3,401 |
| Pantoprazole Sodium | 183 | $2,864 |
| Esomeprazole Magnesium | 62 | $1,258 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 18 | $1,204 |
| Ursodiol | 12 | $1,177 |
| Omeprazole | 115 | $998 |
| Dicyclomine Hcl | 46 | $743 |
| ConstuloseLactulose | 14 | $666 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $918 | $390,49815 claims |
| AbbVieCreon, Linzess | $2,312 | $59,56232 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $2,368 | $51,99518 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $16 | $4,58927 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Dexilant | $1,048 | $3,40111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,448 physician assistant providers in Kentucky.
Other physician assistant in Owensboro
- Jamie BiselOwensboro$11K
- Lauren MahoneyOwensboro$8K
- Brandice HarrisonLexington$745K
- Lauren MeadeLexington$656K
- Melissa DavisLouisville$362K
- Kara MuddLouisville$98K
- Seth KingBowling Green$91K
- Marty MullinsHazard$63K
- Lauri GarnerVersailles$33K
- Robert TatumLouisville$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.